Decision Framework for Antiemetic Therapy in Veterinary Patients

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Antiemetic selection hinges on identifying the dominant emetic pathway (chemoreceptor trigger zone, vagal afferents, vestibular, or central) and matching it to specific drug classes targeting distinct neurotransmitter receptors (e.g., NK1 antagonists for substance P, 5-HT3 antagonists for serotonin, D2 antagonists for dopamine, H1/M1 antagonists for histamine/muscarinic).
• A thorough diagnostic evaluation, including history, physical examination, and appropriate laboratory/imaging studies, must precede antiemetic prescription to avoid masking underlying diseases, particularly in cats with pancreatitis where integrated management is crucial.
• Species-specific pharmacology and metabolism necessitate tailored drug choices; for instance, metoclopramide's efficacy and safety profile differ between dogs and cats, and maropitant is a broad-spectrum option for both.
• Contraindications such as gastrointestinal obstruction or perforation must be identified, as antiemetic use in these scenarios can delay surgical intervention or exacerbate complications.
• Monitoring parameters like vomiting frequency, hydration status, appetite return, and neurological status are critical for assessing therapeutic efficacy, guiding dose adjustments, and detecting adverse effects such as hypotension with phenothiazines or extrapyramidal signs with metoclopramide.
• The evidence base for antiemetic selection is strongest for maropitant in dogs, with limited controlled data in cats and exotic species, leading to reliance on expert opinion for certain clinical scenarios.

Vomiting is a common presenting complaint across companion animal species, yet the choice of antiemetic therapy is frequently made by reflex instead of by structured reasoning. This article provides a decision framework for selecting antiemetic drugs based on the underlying pathophysiologic trigger, the species treated, and the clinical context in which vomiting occurs. It is written for veterinary students and early-career clinicians who need a reproducible method for moving from diagnosis to drug selection without relying on memorised protocols.

The framework answers three sequential questions. First, what is the dominant emetic pathway driving the clinical signs? Second, does the patient's species, disease process, or drug profile impose constraints on the available options? Third, what is the therapeutic goal: immediate symptomatic control, interruption of a specific reflex arc, or prevention of vomiting in a high-risk setting such as chemotherapy or motion sickness? The answers to these questions determine whether a neurokinin-1 receptor antagonist, a 5-HT3 antagonist, a dopamine D2 antagonist, or a histamine/muscarinic antagonist is the most appropriate first choice.

The framework also addresses the diagnostic obligation that precedes antiemetic prescription. Vomiting is a clinical sign, not a diagnosis. Selection of an antiemetic should follow, not precede, a reasonable effort to identify the cause, because the same drug that provides symptomatic relief in one disease may mask progression in another. This is particularly relevant in feline patients, where the ACVIM consensus statement on pancreatitis in cats emphasizes that management decisions must integrate all available clinical and diagnostic information instead of treating vomiting as an isolated event.

At a Glance

Physiology of the Emetic Response

The emetic reflex is coordinated by the vomiting center, a network of nuclei in the medulla that integrates inputs from four principal sources: the chemoreceptor trigger zone (CRTZ), vagal and sympathetic afferents from the gastrointestinal tract, the vestibular system, and higher cortical centers. Each input pathway uses distinct neurotransmitters, which is the basis for drug class selection.

The CRTZ lies outside the blood-brain barrier in the area postrema and responds to blood-borne emetic stimuli, including toxins, uremic metabolites, and drugs. Dopamine D2 and serotonin 5-HT3 receptors dominate this region, making it the primary target for treating metabolic and toxin-induced vomiting. Vagal afferents from the gastrointestinal tract release 5-HT from enterochromaffin cells in response to mucosal irritation, distension, or inflammation, activating 5-HT3 receptors on afferent nerve endings. Vestibular input, relevant in motion sickness, relies on histamine H1 and muscarinic M1 receptors within the vestibular nuclei. Higher cortical input, including fear, pain, and learned aversion, remains poorly characterized pharmacologically but contributes to anticipatory vomiting in some patients.

The final common pathway for the motor act of vomiting involves substance P acting at neurokinin-1 (NK1) receptors in the nucleus tractus solitarius and the vomiting center itself. This explains why NK1 receptor antagonists, such as maropitant, have broad-spectrum antiemetic activity regardless of the initiating stimulus. Understanding this hierarchy allows the clinician to match the drug to the dominant pathway instead of choosing a single agent for all cases.

Pharmacologic Classes and Receptor Targets

Antiemetic drugs are classified by their receptor target, and each class has a characteriztic spectrum of activity. Dopamine D2 antagonists, including metoclopramide and domperidone, are effective against CRTZ-mediated vomiting but have limited efficacy against vagally mediated or vestibular stimuli. Their prokinetic properties add value in gastroparesis but also create a risk of adverse effects when motility is already disordered.

The 5-HT3 receptor antagonists, such as ondansetron and dolasetron, block vagal afferent signaling and CRTZ input. They are particularly useful for chemotherapy-induced emesis and for vomiting associated with gastrointestinal inflammation, but they have no activity against vestibular stimuli. NK1 receptor antagonists, principally maropitant in veterinary medicine, block substance P at the central vomiting center and provide the broadest spectrum of activity across all four input pathways. Maropitant also has visceral analgesic properties that may benefit patients with painful gastrointestinal conditions, although the clinical significance of this effect in spontaneous disease remains an area of ongoing investigation.

Antihistamines and antimuscarinics, including diphenhydramine and scopolamine, target vestibular pathways and are reserved for motion sickness. Their sedative effects and limited efficacy against other emetic stimuli restrict their use to specific prophylactic settings. The choice among these classes is not a matter of equivalence but of matching receptor pharmacology to the identified pathway.

Species Differences in Antiemetic Selection

Canine and feline patients differ in their tolerance of specific drug classes and in the diseases that commonly drive vomiting. Dogs tolerate NK1 receptor antagonism well, and maropitant is widely used as a first-line agent for both acute and prophylactic indications. Cats also tolerate NK1 receptor antagonism, but the ACVIM consensus statement on pancreatitis in cats notes that the evidence base for antiemetic selection in feline pancreatitis is limited, and clinicians must rely on consensus recommendations instead of controlled trials.

Metoclopramide requires caution in both species because of its dopamine antagonist properties, which can produce extrapyramidal signs, particularly in cats. The drug's prokinetic action is also undesirable in patients with suspected mechanical obstruction, where increased motility may exacerbate pain or risk perforation. Species-specific metabolism affects drug clearance, and the clinician should consult current formulary references for species-appropriate dosing instead of extrapolating across species.

Diagnostic Reasoning Before Drug Selection

The decision to administer an antiemetic should be preceded by a structured diagnostic assessment. The minimum database includes a thorough history, physical examination, abdominal palpation, and assessment of hydration and perfusion status. The presence of abdominal pain, a palpable abdominal mass, or signs of peritonitis should redirect the clinician toward surgical evaluation instead of symptomatic therapy. The MSD Veterinary Manual professional edition provides species-specific guidance on the diagnostic approach to vomiting and on the indications for antiemetic therapy in each context.

In patients with acute vomiting and no localizing signs, the clinician must decide whether the cause is likely to be self-limiting, such as dietary indiscretion, or progressive, such as pancreatitis, renal disease, or gastrointestinal obstruction. Antiemetic therapy is appropriate when vomiting itself threatens the patient through fluid loss, electrolyte derangement, or aspiration risk. It is inappropriate when it delays recognition of a surgical abdomen or masks the progression of an underlying disease. The framework therefore requires the clinician to assign a confidence level to the presumptive diagnosis before prescribing, and to define the reassessment interval at which the response to therapy will be evaluated.

The ACVIM consensus statement on pancreatitis in cats illustrates this principle. The statement acknowledges that management of feline pancreatitis is supported by little direct evidence and that treatment decisions must integrate clinical and diagnostic information. In this setting, antiemetic selection is guided by the presumed inflammatory trigger, the patient's hydration status, and the presence of concurrent disease, instead of by a standardized protocol. The same reasoning applies to other diseases in which vomiting is a secondary manifestation, such as chronic kidney disease, hepatic encephalopathy, and diabetic ketoacidosis, where antiemetic therapy supports but does not replace treatment of the primary condition.

Clinical Assessment Sequence for Vomiting Patients

The decision to administer an antiemetic begins with a structured assessment that separates patients requiring immediate intervention from those where antiemetic use could obscure a progressing surgical or toxicologic problem. The sequence follows a fixed order: triage stability, characterize the vomiting pattern, localize the likely trigger, identify contraindications, then select the drug class.

Triage stability comes first. Patients with tachycardia, prolonged capillary refill time, weak pulses, or altered mentation require intravascular volume restoration before any antiemetic is given. Antiemetics do not correct hypovolemia, and many phenothiazines cause vasodilation that can worsen perfusion in a dehydrated patient. The MSD Veterinary Manual professional edition groups antiemetic selection within a broader supportive care framework that prioritizes fluid therapy and correction of electrolyte disturbances before pharmacologic intervention.

Characterize the vomiting pattern next. Acute vomiting of less than 24 hours duration in an otherwise bright patient with normal abdominal palpation often warrants symptomatic treatment without extensive diagnostics. Chronic intermittent vomiting demands a different approach: dietary trials, imaging, and laboratory evaluation precede or accompany antiemetic selection because the drug treats the sign, not the cause. Vomiting accompanied by hematemesis, melena, or abdominal pain shifts the priority toward gastrointestinal protectants and diagnostic imaging instead of antiemetic monotherapy.

Localize the trigger by history and physical examination. Dietary indiscretion, recent medication changes, or access to toxins point toward gastric or chemoreceptor trigger zone stimulation. Vomiting after eating suggests gastric outflow obstruction or gastritis. Vomiting in a fasted patient, particularly in the early morning, suggests reflux or metabolic disease. Young unvaccinated animals with fever and diarrhea raise concern for parvovirus, where antiemetic therapy is supportive but does not replace fluid therapy and infection control. The ACVIM consensus statement on pancreatitis in cats notes that vomiting in feline pancreatitis is often accompanied by anorexia and lethargy, and that management requires attention to pain control and nutritional support alongside antiemetic therapy.

Identify contraindications before dosing. Suspected gastrointestinal foreign body or intussusception is a relative contraindication to antiemetic use until obstruction is excluded, because suppressing vomiting can delay recognition of a surgical abdomen. Patients with known toxin ingestion, particularly of substances metabolized to hepatotoxic intermediates, may benefit from emesis induction instead of suppression depending on timing. Antiemetics that cross the blood-brain barrier, such as maropitant, should be used cautiously in patients with suspected intracranial disease.

Decision Points That Change Drug Selection

The first decision point is species. Dogs and cats differ in receptor distribution and drug metabolism. Maropitant, a neurokinin-1 receptor antagonist, is effective in both species and blocks substance P at the central emetic center and the chemoreceptor trigger zone. Metoclopramide, a D2 dopamine antagonist, is more reliable in dogs than cats because feline D2 receptor density in the chemoreceptor trigger zone is lower. Ondansetron, a 5-HT3 antagonist, works well in both species for chemotherapy-induced and vestibular vomiting.

The second decision point is the suspected emetic pathway. Motion sickness and vestibular disease involve histaminergic and muscarinic pathways, making maropitant less effective as a sole agent. Antihistamines such as diphenhydramine or meclizine target the vestibular apparatus more directly. Chemotherapy-induced vomiting involves 5-HT3 pathways, favoring ondansetron. Renal or hepatic disease with uremia stimulates the chemoreceptor trigger zone through multiple mediators, and combination therapy with maropitant plus ondansetron is often more effective than either alone.

The third decision point is patient status. Hypotensive or hypovolemic patients should not receive phenothiazines such as chlorpromazine or prochlorperazine because of alpha-adrenergic blockade. Patients with hepatic disease require dose adjustment for drugs metabolized by the liver, including maropitant. Patients with renal disease may accumulate metoclopramide and its metabolites. Pregnant animals present a specific challenge: many antiemetics lack safety data in gestation, and the clinician must weigh the risk of uncontrolled vomiting against potential teratogenicity.

The fourth decision point is production setting. In food animals, antiemetic use is uncommon because vomiting is not a typical presenting sign in ruminants, and the drugs approved for companion animals carry withdrawal period considerations that may not be established for food-producing species. The WOAH terrestrial animal health standards address disease surveillance and reporting obligations that may apply when vomiting accompanies suspected notifiable diseases, particularly in swine where vomiting can signal transmissible gastroenteritis or porcine epidemic diarrhea.

Comparative Drug Selection Table

Monitoring Parameters and Their Clinical Meaning

Vomiting frequency is the primary outcome measure but must be interpreted with context. A reduction from six episodes to two episodes in 24 hours represents improvement, yet persistent retching without production of vomitus can indicate gastric outflow obstruction and warrants reassessment. Document each episode with time, volume, content, and whether it was preceded by retching or occurred passively.

Appetite return is a lagging indicator. Many patients remain inappetent for 24 to 48 hours after vomiting ceases, particularly those with pancreatitis or inflammatory bowel disease. The ACVIM consensus statement on pancreatitis in cats emphasizes that nutritional support should begin early in the disease course, and antiemetic therapy is a prerequisite for successful enteral feeding in many cases. If a patient refuses food beyond 72 hours despite adequate antiemetic coverage, reassess the underlying diagnosis instead of escalating antiemetic dose.

Hydration status and body weight track the systemic impact of vomiting. Daily body weight measurement detects fluid losses more reliably than owner observation of water intake. Serum electrolyte monitoring, particularly potassium, sodium, and chloride, identifies the metabolic alkalosis and hypokalemia typical of proximal gastrointestinal losses. Correction of these abnormalities often reduces the emetic stimulus independently of drug therapy.

Neurologic status monitoring applies specifically to metoclopramide and phenothiazines. Restlessness, facial twitching, or extrapyramidal signs require drug discontinuation. Sedation is expected with phenothiazines and antihistamines but should not progress to obtundation. In cats, assess for mydriasis and vocalization, which can indicate dysphoria instead of pain.

Cardiovascular parameters matter for phenothiazines and for high-dose ondansetron. Blood pressure measurement before and 30 minutes after the first phenothiazine dose identifies patients who develop clinically significant hypotension. Heart rate and rhythm monitoring during ondansetron infusion, particularly in patients with pre-existing cardiac disease, detects QT prolongation that can predispose to arrhythmias.

Documentation and Reassessment Triggers

Record the initial assessment findings, the suspected emetic pathway, the drug selected, and the rationale for that choice. Note the route of administration, the time of each dose, and the patient response. Document any adverse effects observed and the action taken. This record supports later reassessment and provides continuity if another clinician assumes care.

Reassess at defined intervals. A patient with acute vomiting should show reduced frequency within 12 to 24 hours of appropriate antiemetic therapy. If vomiting continues unchanged after 24 hours, verify the diagnosis, consider adding a second drug with a different receptor target, or pursue advanced imaging. Failure to respond to maropitant alone in a dog with suspected pancreatitis may reflect inadequate pain control instead of antiemetic failure, and the ACVIM consensus statement on pancreatitis in cats similarly notes that multimodal analgesia is often required before antiemetic efficacy can be assessed.

Escalation triggers include hematemesis, abdominal distension, progressive lethargy, or deterioration in cardiovascular parameters. These findings mandate immediate re-evaluation instead of additional antiemetic dosing. In production animals, vomiting accompanied by fever or multiple animals affected within a herd should prompt consideration of notifiable disease reporting obligations under WOAH terrestrial animal health standards.

De-escalation occurs when vomiting has ceased for 24 hours and the patient is eating and drinking normally. Taper antiemetic therapy instead of abrupt discontinuation, particularly for maropitant, to avoid rebound emesis. Transition from injectable to oral formulations when the patient tolerates oral medication, and discontinue when the underlying condition has resolved.

Recognized Complications and Early Detection

Antiemetic therapy failure is usually detected through persistent vomiting, progressive dehydration, or deterioration in mentation. Recheck the patient at 12 to 24 hours after initiating therapy. Persistent vomiting beyond 24 hours despite an appropriate antiemetic should prompt reassessment of the primary diagnosis instead of addition of a second antiemetic.

Hypotension is the most commonly overlooked complication of phenothiazine antiemetics. Measure blood pressure before and after administration in any patient with suspected hypovolemia, sepsis, or cardiac disease. Serial body weight, packed cell volume, and total protein measurements detect silent fluid loss more reliably than owner observation.

Serotonin receptor antagonist use in cats has been associated with constipation, particularly at higher doses or with prolonged courses. Monitor defaecation frequency and abdominal palpation findings. Metoclopramide can produce behavioral changes, especially in cats, including restlessness, vocalisation, and disorientation. These signs usually resolve within hours of drug discontinuation.

Neuroleptic malignant syndrome is rare but life-threatening. It presents as hyperthermia, muscle rigidity, and altered consciousness in animals receiving dopamine receptor antagonists. Check rectal temperature and muscle tone in any patient that becomes obtunded after antiemetic administration.

Common Errors and Corrective Actions

Students and less experienced clinicians frequently select an antiemetic before establishing whether vomiting is central or peripheral in origin. A patient with vestibular disease and motion-induced vomiting will respond poorly to maropitant alone. The corrective action is to identify the afferent pathway before choosing the drug.

A second common error is treating all vomiting as gastric in origin. Pancreatitis in cats frequently presents with vomiting that responds incompletely to antiemetic monotherapy. The ACVIM consensus statement on pancreatitis in cats emphasizes that management must address pain, hydration, and nutritional support alongside antiemetic therapy, and that antiemetic selection should follow from the diagnosis instead of precede it ACVIM consensus statement on pancreatitis in cats.

Another error is continuing antiemetic therapy without reassessing the need for it. Once the underlying cause is controlled, taper the antiemetic instead of stopping abruptly, particularly after several days of treatment. Rebound vomiting can occur when dopamine receptor antagonists are withdrawn quickly.

Clinicians also err by withholding antiemetics in patients with suspected infectious enteritis. Vomiting in salmonellosis contributes to fluid and electrolyte losses that worsen outcome. The decision to use an antiemetic should rest on the severity of vomiting and the patient's hydration status, not on the presumed infectious aetiology alone. Human outbreak data show that supportive care, including control of vomiting and diarrhea, is central to reducing morbidity in salmonellosis nationwide trends and features of human salmonellosis outbreaks in China.

Finally, some clinicians fail to document the indication for antiemetic use, the response to therapy, and the reassessment plan. This omission complicates subsequent care and medicolegal review. Record the suspected emetic pathway, the drug chosen, the route, the response at 12 and 24 hours, and the planned duration of therapy.

Limitations of the Evidence and Areas of Expert Disagreement

The evidence base for antiemetic selection in veterinary patients is uneven. Most published data concern maropitant in dogs, with comparatively little work in cats and almost none in exotic or production species. The ACVIM pancreatitis consensus acknowledges that management recommendations in cats rest largely on expert opinion instead of controlled trials ACVIM consensus statement on pancreatitis in cats.

Expert opinion differs on several points. Some specialists advocate combination therapy with maropitant and a dopamine receptor antagonist for severe or refractory vomiting, while others caution that combination therapy increases the risk of adverse effects without proven benefit. There is no consensus on the optimal duration of antiemetic therapy after resolution of clinical signs.

The role of antiemetics in animals with suspected toxin ingestion remains contested. Some experts recommend against antiemetic use when the toxin may still be present in the gastrointestinal tract, while others argue that the risks of aspiration and metabolic derangement outweigh this concern. No controlled studies resolve this question.

Referral, Consultation, and Reporting

Referral to a specialist is warranted when vomiting persists beyond 48 hours despite appropriate therapy, when the diagnosis remains unclear after initial imaging and laboratory testing, or when the patient requires advanced imaging such as computed tomography or endoscopy. Patients with suspected intracranial disease, refractory pancreatitis, or suspected surgical abdomen should be referred without delay.

Laboratory involvement is indicated when cytology, histopathology, or specialised testing such as pancreatic lipase immunoreactivity or bile acid measurement is needed. The Davis-Thompson Foundation provides pathology case material and diagnostic resources that can support interpretation of biopsy and cytology findings Davis-Thompson Foundation veterinary pathology resources.

Regulatory reporting may be required when vomiting is part of a suspected notifiable disease, a suspected adverse drug reaction, or a food safety event involving production animals. Consult the relevant national veterinary authority and the World Organization for Animal Health terrestrial standards for disease reporting obligations WOAH terrestrial animal health standards. Reporting requirements differ by jurisdiction and species, so confirm local obligations before acting.

Frequently Asked Questions

How do I choose an antiemetic when cost limits the options?

When budget constrains the formulary, rank drugs by receptor coverage and safety margin instead of by acquisition cost. Maropitant covers central and peripheral NK1 pathways and suits most canine and feline cases, making it the default cost-effective choice. Metoclopramide costs less but requires a constant-rate infusion for reliable effect and covers only D2 and 5-HT3 pathways, leaving NK1-mediated stimuli untreated. Ondansetron as a sole agent fails against motion sickness and central triggers. Reserve the least expensive option for patients with mild, self-limiting vomiting and no systemic signs. Reassess within 24 hours, and escalate if vomiting frequency does not decline. The MSD Veterinary Manual provides comparative pharmacology summaries that support formulary decisions.

What should I do when injectable antiemetics are unavailable?

Oral administration is acceptable only when vomiting is infrequent and the patient retains water. Give the oral dose, observe for 30 to 60 minutes, and proceed with small-volume fluid challenges if no further vomiting occurs. When oral dosing fails or the patient vomits repeatedly, use a transdermal or compounded preparation only if the drug has documented absorption in the target species. Otherwise, manage supportively with intravenous fluids, fasting for 6 to 12 hours in dogs, and gradual reintroduction of a bland diet. Cats with hepatic lipidosis risk should not fast beyond 12 hours. The ACVIM consensus statement on pancreatitis in cats notes that supportive care alone may suffice in mild feline pancreatitis, but antiemetic coverage is still advised when vomiting impairs oral intake.

How does my approach change for a vomiting rabbit or ferret?

Rodents and lagomorphs cannot vomit, so antiemetic therapy is irrelevant in rabbits, guinea pigs, and chinchillas. Ferrets vomit readily and respond to maropitant, but their rapid gastrointestinal transit means dehydration develops quickly. In ferrets, treat the underlying cause first, typically gastritis, foreign body, or systemic disease, and use an antiemetic only as an adjunct while diagnostics proceed. Never assume a rabbit with regurgitation has gastric disease, dental disease and ileus are more common. The MSD Veterinary Manual species-specific sections outline these differences and warn against extrapolating canine dosing logic to exotic carnivores.

What must I document when prescribing an antiemetic off-label?

Record the drug, route, frequency, and the specific indication that justifies extrapolation from the labelled species. Note the owner's informed consent, including discussion of unproven efficacy and potential adverse effects. Document the baseline examination findings, including hydration status, abdominal palpation, and body weight, so response assessment is objective. Log each reassessment, the vomiting frequency since the last visit, and any dose adjustments. For food-producing animals, verify the withdrawal interval using current label references before dispensing. The AVMA practice resources address professional obligations around extralabel drug use and record keeping.

When should I stop antiemetic therapy instead of continue it?

Stop the antiemetic when the patient has gone 24 hours without vomiting while eating and drinking normally. Tapering is unnecessary for maropitant or ondansetron in most patients. Continue therapy longer when the underlying cause persists, such as chemotherapy-induced emesis or chronic pancreatitis. Re-evaluate before each refill, and do not renew beyond 72 hours without re-examining the patient. If vomiting recurs after discontinuation, restart the same drug and pursue further diagnostics instead of cycling through alternatives. Persistent vomiting despite adequate antiemetic coverage warrants imaging and laboratory reassessment, as the ACVIM consensus statement on pancreatitis in cats emphasizes for feline patients with refractory signs.

How do I explain antiemetic selection to a client who expects a single injection to cure vomiting?

Clarify that the antiemetic controls the sign, not the cause. Explain that the drug blocks the brain's vomiting signal, giving the gastrointestinal tract time to heal, but that diagnostics determine why the vomiting started. Use the analogy of a smoke alarm: silencing the alarm does not put out the fire. Describe what the owner should monitor, specifically vomiting frequency, appetite, energy level, and water intake, and give a concrete threshold for calling back, such as two or more vomiting episodes in 12 hours. Reassure them that most patients respond within 24 hours, but that failure to improve changes the plan. The MSD Veterinary Manual offers client-facing summaries that reinforce this message.

Related Clinical & Scientific Guides

• Hypersensitivity Reactions: Types and Mechanisms
• Therapeutic Decision-Making for Respiratory Infections in Cattle
• Monitoring Fluid Therapy in Critically Ill Veterinary Patients

References and Further Reading

• ACVIM consensus statement on pancreatitis in cats.. 2021.
• Nationwide trends and features of human salmonellosis outbreaks in China.. 2024.
• Davis-Thompson Foundation Veterinary Pathology Resources. Davis-Thompson Foundation.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.
• WOAH Terrestrial Animal Health Code. WOAH.

Related Articles

• Decision Framework for Anticoagulant Therapy in Veterinary Patients
• Decision Framework for Choosing Antifungal Therapy in Veterinary Patients
• Decision Framework for Antihypertensive Therapy in Veterinary Patients
• Decision Framework for Antiviral Therapy in Veterinary Patients
• Decision Framework for Antiparasitic Therapy in Companion Animals

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.